$INSM — dispatch coverage
47 public MyJunto dispatches mentioning $INSM, newest first.
Analyst stance
4 tracked analysts4 bullish
- @biotech2k1-0.8%bullish
- @adamfeuerstein-4.1%bullish
- @deitaone-24.0%bullish
- @intheassembly-24.4%bullish
Dispatches
- ESMO Embargo Breach Resets Melanoma Vaccine Narrative; $IOVA's Real-World Durability + NSCLC TAM Now The StoryOct 23, 2026Biotech + AI Investors
- $IOVA's ESMO Catalyst Sequence Locks $20–25 Target; $INSM's DPP1 Platform Unlocks Hidden $10B+ TAMOct 22, 2026Biotech + AI Investors
- $IOVA's ESMO Data Lock + NSCLC TAM Expansion Justify $20–25 EOY; $INSM's DPP1 Platform Surfaces $10B+ Brinsupri UpsideOct 21, 2026Biotech + AI Investors
- $IOVA's ESMO + NSCLC Catalysts Lock 1H27 M&A Window; $INSM's Brinsupri Upside Breaks Through Valuation CompressionOct 20, 2026Biotech + AI Investors
- $IOVA's ESMO Data Drop Sets Up 1H27 M&A Window; Protein-Design Commodity Layer Stays InertOct 19, 2026Biotech + AI Investors
- $INSM Patent Defense Holds; Biotech-AI Infrastructure Remains Commodity—No Near-Term Commercial SignalOct 16, 2026Biotech + AI Investors
- Protein Design Tools Now Table-Stakes; $IOVA M&A Thesis Remains Only Near-Term Biotech-AI SignalOct 15, 2026Biotech + AI Investors
- AI-Protein Design Tools Proliferate; Biotech-AI Infrastructure Thesis Hardens but No Near-Term Commercial CatalystOct 13, 2026Biotech + AI Investors
- Insilico's Frontier-Model Co-Dev Deal Signals AI-Biotech Infrastructure Play—Generative Biology Moat NarrowsSep 23, 2026Biotech + AI Investors
- $IOVA ESMO Catalyst + Wayne Rothbaum Execution Lock Q4 Conviction—TIL Manufacturing Moat Compounds Across IndicationsSep 22, 2026Biotech + AI Investors
- $IOVA Amtagvi + Keytruda Combo Data (ESMO Oct 23–27) Locks Q4 Catalyst—Conviction Reset Incoming on Multi-Indication ScaleSep 21, 2026Biotech + AI Investors
- $IOVA Guidance Reset + Texas Oncology Expansion Lock Conviction Into Q4 Catalyst—Manufacturing Inflection Priced as Single-Asset StorySep 18, 2026Biotech + AI Investors
- $NRTX IPO Launch Signals Fresh AI-Embedded Immunotherapy Wave—IL-13xIL-18 Bispecific Enters Crowded Atopic Dermatitis RingSep 17, 2026Biotech + AI Investors
- AI-Embedded TIL Infrastructure Locks Biotech Moat—$IOVA Commands Cell-Therapy Leadership on Manufacturing + Pipeline ScaleSep 16, 2026Biotech + AI Investors
- AI-Embedded Antibody Platforms Lock In Manufacturing Edge—Multi-Modal Protein Design Now Production-ReadySep 9, 2026Biotech + AI Investors
- $ABVX M&A Stalemate + $QURE Confirmatory Trial Lock-In—Single-Modality Biotech Trap WidensSep 4, 2026Biotech + AI Investors
- $IOVA Profitability Lock-In—M&A Window Hardens as NSCLC Interim (Sept–Oct) Collapses Remaining HedgesSep 3, 2026Biotech + AI Investors
- $IOVA Inflection Lock-In—Manufacturing Scale Signals M&A Window While NSCLC Interim (Sept–Oct) Collapses HedgesSep 2, 2026Biotech + AI Investors
- $IOVA Polyclonal TIL Moat Widens—UAE Sovereignty + NSCLC Interim (60–90 Days) Collapse Shorts While AI-Biotech Bubble LiquidatesSep 1, 2026Biotech + AI Investors
- $IOVA Escapes Biotech Bubble—UAE Sovereign Visit + Cell-Free DNA Durability Signal Validate TIL Moat While Peers CollapseAug 31, 2026Biotech + AI Investors
- $IOVA Inflection Locked—UAE Delegation Tour Signals M&A Window; $ALNY Silencer Catastrophe Bleeds Into Broader AI-Biotech Moat DebateAug 28, 2026Biotech + AI Investors
- $RVMD FDA Approval—Hype Over Pharmacology Exposes Biotech Bubble's DepthAug 27, 2026Biotech + AI Investors
- Biotech Valuation Bubble Now Undeniable—$IOVA Remains Outlier as Sector Consensus FracturesAug 26, 2026Biotech + AI Investors
- $IOVA Reprices Into Acquisition Territory — TIL Moat Now Undeniable, $15–$20 Range Credible Before 2H27 NSCLCAug 18, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 17Aug 17, 2026Biotech + AI Investors
- $IOVA & $AQST Lock AI-Biotech Thesis — TIL Cell Therapy + AI-Optimized Drug Design Now Clinical ProofAug 14, 2026Biotech + AI Investors
- AI-Designed Drugs Clear Regulatory Hurdle — $AQST NDA Path Now Live, Biotech-AI Thesis HardensAug 13, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 7Aug 7, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 6Aug 6, 2026Biotech + AI Investors
- Biotech + AI Investors — Aug 3Aug 3, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 31Jul 31, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 29Jul 29, 2026Biotech + AI Investors
- INSUFFICIENT IN-SCOPE MATERIAL — DISPATCH WITHHELDJul 28, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 27Jul 27, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 23Jul 23, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 22Jul 22, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 21Jul 21, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 20Jul 20, 2026Biotech + AI Investors
- Avere Launches as Long-Acting I&I Pivot—Ex-Akero Team Signals Execution Bet Over Protein Design HypeJul 14, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 13Jul 13, 2026Biotech + AI Investors
- Wainua Collapse Hardens AI-Gated Developability as Clinical Moat—Rotation Accelerates Into Execution-Proven BiotechJul 10, 2026Biotech + AI Investors
- VRTX's $10B CRNX Buyout Signals Consolidation—Biotech-AI Moat Gap WideningJul 7, 2026Biotech + AI Investors
- ADC Payload Innovation + Protein Design AI — Narrow Window of Biotech-AI ConvergenceJul 6, 2026Biotech + AI Investors
- Biotech + AI Investors — Jul 3Jul 3, 2026Biotech + AI Investors
- Biotech + AI Investors — Jun 29Jun 29, 2026Biotech + AI Investors
- Biotech + AI Investors — Jun 26Jun 26, 2026Biotech + AI Investors
- Pfizer's Lung Cancer ADC Stumble Opens Door for AI-Native Competitors; Lilly's Obesity Play Signals Regulatory FlexibilityJun 23, 2026Biotech + AI Investors